Silo Pharma SILO 深 滬
等待開盤 09-24 09:30:00 美东时间
1.77
+0.050
+2.91%
華盛通- 最 高1.84
- 今 開1.74
- 成交量 4.44万股
- 最 低 1.74
- 昨 收 1.72
- 總市值 310.33万
- 52周最高 10.8675
- 市盈率 靜 --
- 換手率 2.54%
- 52周最低 1.63
- 委 比 -61.94%
- 總股本 175.33万
- 歷史最高 108.90
- 量 比 0.42
- 振 幅 5.81%
- 歷史最低 1.74
- 每 手 1
- 風險率 2.02%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Silo Pharma Receives U.S. Patent Office Notice Of Allowance For Application Covering SPC-15, Its Novel Intranasal Therapeutic Targeting Post-Traumatic Stress Disorder
The invention, titled "Compositions and Methods for the Prevention of Stress-Induced Fear, Depressive-Like and Anxiety-Like Behavior," is also covered by a corresponding patent issued by the Japan Patent Office earlier this year. Silo’s Chief Executive Officer Eric Weisblum commented, "Securing U.S....
09-18 20:52
Silo Pharma Receives U.S. Patent Allowance for SPC-15 PTSD Treatment, Expanding Intellectual Property Portfolio
Silo Pharma announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application covering its lead asset, SPC-15, a novel intranasal therapeutic targeting post-traumatic stress disorder (PTSD). The invention, titled “Compositions and Methods for the Prevention of Stress-Induced Fear, Depressive-Like and Anxiety-Like Behavior,” is also covered by a corresponding patent issued by the Japan Patent Office earl...
09-18 12:50
Silo Pharma to Highlight Patented Nose-to-Brain Drug Delivery Technology for PTSD at 2026 Nasal Innovation Forum
Silo Pharma announced its participation in the IPAC-RS 2026 Nasal Innovation Forum to discuss its novel nose-to-brain drug delivery system, SPC-15, for PTSD treatment. The company highlighted preclinical data supporting SPC-15's stability and performance. Silo Pharma focuses on innovative therapies for underserved conditions, leveraging its AI subsidiary, QwikAgents, for research and automation.
09-09 13:15
Silo Pharma Says Canadian Intellectual Property Office Issues Notice Of Allowance For Patent Application Covering SPC-15, Intranasal 5-HT4 Receptor Agonist Targeting PTSD And Other Stress-Induced Psychiatric Disorders
Follows recent European patent grant and coverage in multiple international markets as Silo continues to strengthen licensed IP portfolio for lead therapeutic program SARASOTA, FLA., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (NASDAQ:SILO) ("Silo" or "the Company"), a developmental-stage biopharm...
08-19 04:16
Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment
Silo Pharma announced that the Canadian Intellectual Property Office has granted a Notice of Allowance for a patent application covering its lead asset, SPC-15, an intranasal 5-HT4 receptor agonist targeting PTSD and other stress-induced psychiatric disorders. The patent, titled "Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress," covers methods of preventing stress-induced fear and enhancing stress resilience. Corresponding p...
08-18 20:15
Silo Pharma’s QwikAgents Engages AWS Premier Tier Services Partner Caylent To Design And Build AWS-Native QwikAgents Platform
Collaboration supports development of a next-generation AWS-native platform designed to accelerate commercialization, scalability and enterprise adoption SARASOTA, FLA., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (NASDAQ:SILO) ("Silo" or "the Company"), a managed AI agent platform and development...
08-06 20:52
Silo Pharma Engages Drug-Device Development Partner Resyca To Carry Out Trial To Evaluate Nasal Spray System For Nose-To-Brain Delivery Of SPC-15 To Treat Post-Traumatic Stress Disorder
Silo Pharma (NASDAQ:SILO) ("Silo" or "the Company"), a diversified developmental-stage biopharmaceutical company with a therapeutic focus on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases, today announced tha...
06-30 04:17
Silo Pharma Confirms Nine‑Month Stability Of SPC‑15 Intranasal Prophylactic, Supporting IND‑Enabling CMC Documentation.
Positive data supports the continued advancement of FDA Investigational New Drug (IND)- enabling development program SARASOTA, FLA., June 23, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (NASDAQ:SILO) ("Silo" or "the Company"), a developmental-stage biopharmaceutical company focused on novel therapeutics an...
06-23 20:19
SILO Pharma Q1 EPS $(0.12) Up From $(0.23) YoY, Sales $18.026K, Same YoY
SILO Pharma (NASDAQ:SILO) reported quarterly losses of $(0.12) per share. This is a 47.83 percent increase over losses of $(0.23) per share from the same period last year. The company reported $18.026 thousand in sales
05-15 04:20
